Spots Global Cancer Trial Database for tasigna
Every month we try and update this database with for tasigna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT01528085 | Philadelphia Ch... | Nilotinib | 55 Years - | Goethe University | |
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | NCT01261429 | Pigmented Villo... | Tasigna | 18 Years - | Centre Leon Berard | |
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | NCT01261429 | Pigmented Villo... | Tasigna | 18 Years - | Centre Leon Berard | |
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) | NCT01270893 | Gastrointestina... | Nilotinib | 18 Years - | M.D. Anderson Cancer Center | |
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib | NCT01223898 | Chronic Myeloid... | Tasigna | 18 Years - | Novartis | |
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | NCT01261429 | Pigmented Villo... | Tasigna | 18 Years - | Centre Leon Berard | |
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment | NCT00980018 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis |